Best Business Magazine in World | Swiftnlift
no image

Urotronic, Inc. - Break The Stricture Cycle With Optilume

Urotronic Inc. is a medical device startup that is working on drug/device combo solutions.

Our objective is to create ground-breaking solutions that will revolutionize the urology market by improving patient outcomes in a way that is uniquely suited to today's healthcare environment.

Urotronic's Drug Coated Balloon (DCB)—Optilume—is an intriguing urology invention that was prompted by severe patient and physician dissatisfaction with conventional stricture therapies.

Potential for long-term relief

The Optilume drug-coated balloon is an intriguing, minimally invasive urethral stricture treatment that was created in response to severe patient and physician dissatisfaction with conventional stricture remedies.

Patients tolerate this innovative method, which combines balloon dilation and medication delivery.

The highly lipophilic medication paclitaxel restricts hyperactive cell growth and the formation of fibrotic scar tissue, which leads to stricture recurrence.

Balloon dilation and medication delivery are combined in this patented method.

The highly lipophilic medicine paclitaxel restricts hyperactive cell growth and the formation of fibrotic scar tissue, which leads to stricture recurrence.

Specialties

Medical Device, Engineering, Start up, Urology, Drug Coated Balloon, and Stricture

How it works.

The Optilume process is straightforward to learn and perform because it is identical to regular mechanical dilation.

The semi-compliant balloon swells into the tissue, causing micro-fissures that aid medication absorption throughout the circumference.

  • Inflates.

The balloon inflates to create micro-fissures in the tissue, providing a pathway for drug absorption.

  • Releases.

Hydrophilic coating facilitates the rapid release of paclitaxel.

  • Delivers.

Hydrophobic and lipophilic properties support rapid cellular uptake—enabling the drug to pass through the urethral wall and take up residency in the tissue.

The stricture

  • Breakthrough

Optilume intends to provide long-term relief from stricture recurrence by combining a simple, effective balloon dilatation with targeted application of a proven ant proliferative.

  • Paclitaxel and coating

A novel excipient molecularly binds paclitaxel to the balloon until the balloon inflates and dilates the tissue for rapid, controlled drug release.

  • Optilume benefits.

Ends the high recurrence cycle of failed endoscopic stricture management

Minimally invasive

Compatible with flexible cystoscopes for maximum patient comfort

Balloon dynamic compliance provides optimal expansion for urology applications

  • Industry : Medical Device

  • Company size : 2-10 employees

  • Headquarters : Plymouth, MN

  • Type : Privately Held

  • Founded : 2015